XML 35 R23.htm IDEA: XBRL DOCUMENT v3.20.4
Note 16 - Segment Reporting
 6 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
16.
Segment reporting
 
The Company's chief operating decision maker (the “CODM”), who is the Company's Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.
 
The Company manages and aggregates its operational and financial information in accordance with
two
reportable segments: Aytu BioScience and Aytu Consumer Health. The Aytu BioScience segment consists of the Company's prescription products. The Aytu Consumer Health segment contains the Company's consumers healthcare products, which was the result of the Innovus Merger. Select financial information for these segments is as follows:
 
   
Three months Ended December 31,
    
Six Months Ended December 31,
  
   
2020
    
2019
    
2020
    
2019
  
Consolidated revenue:
                                
Aytu BioScience
   $
7,212,000
     $
3,175,000
     $
13,000,000
     $
4,615,000
  
Aytu Consumer Health
    
7,935,000
      
-
      
16,000,000
      
-
  
Consolidated revenue
    
15,147,000
      
3,175,000
      
29,000,000
      
4,615,000
  
                                 
Consolidated net loss:
                                
Aytu BioScience
    
(8,267,000
 )    
(214,000
 )    
(11,218,000
 )    
(5,143,000
 )
Aytu Consumer Health
    
(1,258,000
 )    
-
      
(2,613,000
 )    
-
  
Consolidated net loss
    
(9,525,000
 )    
(214,000
 )    
(13,831,000
 )    
(5,143,000
 )
 
   
As of
    
As of
  
   
December 31,
    
June 30,
  
   
2020
    
2020
  
Total assets:
                
Aytu BioScience
   $
140,647,000
     $
126,267,000
  
Aytu Consumer Health
    
26,095,000
      
26,569,000
  
Total assets
   $
166,742,000
     $
152,836,000